Article

ChemInform Abstract: Adverse Reactions and Drug-Drug Interactions in the Management of Women with Postmenopausal Osteoporosis

Division of Bone Disease, Department of Rehabilitation and Geriatrics, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.
Calcified Tissue International (Impact Factor: 2.75). 06/2011; 89(2):91-104. DOI: 10.1007/s00223-011-9499-8
Source: PubMed

ABSTRACT The pharmacological management of disease should involve consideration of the balance between the beneficial effects of treatment on outcome and the probability of adverse effects. The aim of this review is to explore the risk of adverse drug reactions and drug-drug interactions with treatments for postmenopausal osteoporosis. We reviewed evidence for adverse reactions from regulatory documents, randomized controlled trials, pharmacovigilance surveys, and case series. Bisphosphonates are associated with gastrointestinal effects, musculoskeletal pain, and acute-phase reactions, as well as, very rarely, atrial fibrillation, atypical fracture, delayed fracture healing, osteonecrosis of the jaw, hypersensitivity reactions, and renal impairment. Cutaneous effects and osteonecrosis of the jaw are of concern for denosumab (both very rare), though there are no pharmacovigilance data for this agent yet. The selective estrogen receptor modulators are associated with hot flushes, leg cramps, and, very rarely, venous thromboembolism and stroke. Strontium ranelate has been linked to hypersensitivity reactions and venous thromboembolism (both very rare) and teriparatide with headache, nausea, dizziness, and limb pain. The solidity of the evidence base depends on the frequency of the reaction, and causality is not always easy to establish for the very rare adverse reactions. Drug-drug interactions are rare. Osteoporosis treatments are generally safe and well tolerated, though they are associated with a few very rare serious adverse reactions. While these are a cause for concern, the risk should be weighed against the benefits of treatment itself, i.e., the prevention of osteoporotic fracture.

Download full-text

Full-text

Available from: John A Kanis, Jul 07, 2015
1 Follower
 · 
269 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The aims of this study were to evaluate the osteoprotective effect of aqueous extract from Rhizoma Dioscoreae (RDE) on rats with ovariectomy- (OVX-) induced osteopenia. Our results show that RDE could inhibit bone loss of OVX rats after a 12-week treatment. The microarray analysis showed that 68 genes were upregulated and that 100 genes were downregulated in femurs of the RDE group rats compared to those in the OVX group. The Ingenuity Pathway Analysis (IPA) showed that several downregulated genes had the potential to code for proteins that were involved in the Wnt/ β -catenin signaling pathway (Sost, Lrp6, Tcf7l2, and Alpl) and the RANKL/RANK signaling pathway (Map2k6 and Nfatc4). These results revealed that the mechanism for an antiosteopenic effect of RDE might lie in the synchronous inhibitory effects on both the bone formation and the bone resorption, which is associated with modulating the Wnt/ β -catenin signaling and the RANKL/RANK signaling.
    The Scientific World Journal 01/2014; 2014:645975. DOI:10.1155/2014/645975 · 1.73 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Bone density measurements play an important part in the categorisation of osteoporosis as a risk factor in modern medicine. According to the World Health Organization, people are categorised as having osteoporosis when their bone mineral density (BMD) value is 2.5 standard deviation (SD) below the young adult mean value, and as having osteopenia when the value lies between one and 2.5 SDs below the young adult mean value. The categorisation according to SDs makes osteoporosis a rather unique case within the medical world of risk definitions. We invited women who had their bone mass scanned in the Nord-Trøndelag Health Study (HUNT) to participate in focus groups and share their scanning experiences. Nine groups of women met three times for a total of 27 focus group discussions. Our findings illustrate that having their BMD measured contributed to a substantial confusion, related in particular to feedback given as SDs, the choice of reference populations and the body sites chosen for BMD. Some of the women had had their BMD measured at different health institutions using different reference groups, which resulted in women being told that they were osteoporotic at one institution, but not at the other. As the different institutions also scanned various body sites, including the wrist, hip and spine, the women were also confused about what site(s) provides the best information about their bone status. Overall this study shows that osteoporosis presents us with a particularly challenging example of risk categorisation.
    Health Risk & Society 04/2012; 14(2):191-206. DOI:10.1080/13698575.2012.661408 · 1.13 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Guidance is provided in a European setting on the assessment and treatment of postmenopausal women with or at risk from osteoporosis. The European Foundation for Osteoporosis and Bone disease (subsequently the International Osteoporosis Foundation) published guidelines for the diagnosis and management of osteoporosis in 1997. This manuscript updates these in a European setting. The following areas are reviewed: the role of bone mineral density measurement for the diagnosis of osteoporosis and assessment of fracture risk; general and pharmacological management of osteoporosis; monitoring of treatment; assessment of fracture risk; case finding strategies; investigation of patients; health economics of treatment. A platform is provided on which specific guidelines can be developed for national use.
    Osteoporosis International 05/2008; 19(4):399-428. DOI:10.1007/s00198-008-0560-z · 4.17 Impact Factor